Michelle Bragazzi, Managing Editor, OncoTherapy Network | Authors

NORTHEAST GEORGIA HEALTH SYSTEM

Articles

XRCC2 Gene May Contribute to Testicular Cancer Treatment Resistance

February 05, 2015

Scientists from The Institute of Cancer Research in London identified a gene which may contribute to testicular cancer treatment resistance.

Polynoma Launches Phase III Melanoma Vaccine Trial

January 30, 2015

A multicenter, double-blind, placebo-controlled, phase III vaccine trial is now underway for post-resection melanoma patients with a high risk of recurrence.

EZH2 Protein May Contribute to Melanoma Metastasis

January 29, 2015

Because of the high mutation rate in melanoma cells, cancer drugs have been developed to help target these signaling pathways that stimulate such rapid growth. While many of these drugs have proven to be successful, resistance to these same drugs can also occur.

Melanoma IHC Test Useful for Detecting BRAF V600E Mutations

January 27, 2015

When it comes to cutaneous malignant melanoma (CMM), BRAF V600E is a common mutation found in approximately 50% of cases. Currently, BRAF mutations are detected by using DNA tests, but there may be an alternative assay that's less expensive, requires less tissue, more efficient, and thought to be more sensitive.